Pharmaceutical Industry

Trias Pharma GmbH 

Winterthur · Since 2016

The core activity of Trias Pharma GmbH is the development and manufacture of solid dosage forms, in particular oral dosage forms such as tablets and soft capsules, as well as the provision of analytical support services and expertise in the field of drug development, including the development of medical cannabis.

Trybol AG 

Neuhausen Am Rheinfall · Since 1900

The core activity of Trybol AG is the manufacture, filling and packaging of cosmetics and toiletries. The company develops and markets its own recipes and branded products and also produces on a contract manufacturing and contract filling basis for other companies.

ufamed AG 

Sursee · Since 1969

The core activity of ufamed AG is the development, manufacture and marketing of products for animal health and care, including biocidal products, dietary and supplementary feed, care products and veterinary medicinal products. The company also provides consulting services for animal owners and veterinarians.

Ultimate Medicine AG 

Zurich · Since 2020

Ultimate Medicine AG develops small-molecule therapeutics targeting a novel toxic metabolite that disrupts neuronal functions and accelerates progression of Alzheimer's disease and other dementias. Its lead program is an oral small-molecule inhibitor designed to block metabolite synthesis and thereby reduce systemic and brain exposure through natural clearance mechanisms.

Ultragenyx Europe GmbH 

Basel · Since 2016

Ultragenyx Europe GmbH is a biopharmaceutical company that develops therapies for rare and ultra-rare genetic diseases and researches multiple drug modalities, including gene therapy. The company maintains a clinical pipeline, provides approved medicines such as DOJOLVI and MEPSEVII, and operates patient support programs.

Unixis AG 

Zofingen · Since 2022

Unixis AG provides CDMO services for pharmaceutical cannabis products, including product development, sourcing, manufacturing, packaging and market entry. The company holds Swissmedic licences for controlled substances and GDP approvals, conducts licensed import/export of THC flowers, and runs a cGMP pilot project to produce high‑purity THC distillate in partnership with Siegfried AG.

UR Health GmbH 

Marbach Lu · Since 2018

The core activity of UR Health GmbH is the commercialization of pharmaceutical products, particularly in the DACH region. The company offers services such as distribution, marketing and communication for pharmaceutical manufacturers to successfully place their products on the market. It has comprehensive knowledge of the pharmaceutical market, a broad network of partners and good personal contacts with decision-makers.

Urovant Sciences GmbH 

Basel · Since 2016

Urovant Sciences GmbH is a pharmaceutical company focused on research, development and commercialization of therapies in urology, including treatments for overactive bladder such as Vibegron.

Ursapharm Schweiz GmbH 

Hünenberg · Since 1998

The core activity of URSAPHARM is the development, manufacture and marketing of pharmaceutical products, in particular eye care products such as HYLO and EvoTears, as well as systems and manufacturing solutions for the pharmaceutical industry.

Vaccentis AG 

Zurich · Since 2006

The core activity of Vaccentis AG is the development of tumor vaccines, particularly through the use of the individualized precision immunotherapy platform AIPI (ALL INDIVIDUALIZED PRECISION IMMUNOTHERAPY TUMOUR VACCINE TECHNOLOGY PLATFORM).

Vaderis Therapeutics AG 

Basel · Since 2020

The core activity of Vaderis Therapeutics AG is the development of medications, particularly in the areas of rare diseases, nephrology, vascular diseases, fibrosis, anti-infectives, and immunology. The company focuses on the early clinical development of new molecules and has experience in collaborating with companies such as Novartis.

Valentis AG 

Agno · Since 2011

The core activity of Valentis is the development, production and distribution of natural medical products, including dietary supplements, plant-based products, medical devices and liquid nutraceuticals, with a focus on nanotechnology. The company also offers contract manufacturing and private label production for other companies.

Valerius Biopharma AG 

Reinach Bl · Since 2017

Valerius Biopharma AG develops biosimilars and manages a portfolio of orphan and non‑orphan candidates, conducting R&D on cell lines, process development and extensive analytical characterization.

VAMEDIS Swiss GmbH 

Diepoldsau · Since 2006

Vandria SA 

Epalinges · Since 2021

Vandria SA is a clinical-stage biotech company developing first-in-class small molecules against a novel metabolic target to restore mitochondrial function and reduce chronic inflammation for the treatment of age-related and chronic diseases. Its lead clinical CNS asset, VNA-318, is an orally available, brain-penetrant small molecule that completed Phase I studies demonstrating safety, tolerability and a pharmacokinetic profile suitable for once-daily oral dosing.

Vantive Health GmbH 

Glattpark (Opfikon) · Since 2023

Vaximm AG 

Basel · Since 2008

The core activity of VAXIMM is the development of oral T-cell immunotherapies for cancer patients.

VB Technochemicals SA 

Chiasso · Since 1993

The core activity of VB Technochemicals SA encompasses the development, production and distribution of chemical and pharmaceutical products, particularly barium and zinc derivatives, as well as the manufacture of pharmaceutical solutions for various therapeutic areas. The company also provides distribution, marketing and regulatory services.

Aspeya Switzerland SA 

Lausanne · Since 2024

Aspeya Switzerland SA develops and commercializes wellness and healthcare products and brands, focusing on consumer health, cannabinoid applications (via its Verdeya subsidiary), and inhaled therapeutics. The company applies scientific research and product development and leverages the oral-technology platform of Fertin Pharma, a contract development and manufacturing organization owned by Aspeya, to develop scalable formulations and delivery systems.

Versameb AG 

Basel · Since 2017

The core activity of Versameb is the development of therapeutic solutions, particularly in the fields of dermatology, oncology and mycology, based on a proprietary platform technology.